Biomarker & Intervention Discovery

Atopic Dermatitis (Eczema)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Spontaneous remission60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent…
Best-intervention remissionDupilumab (anti-IL-4Rα): 51% IGA 0/1 (clear/almost clear) at 16 weeks in SOLO trials; tralokinumab (anti-IL-13): 38%…
Gap sizeLarge — most patients managed with topical steroids for decades without biologic assessment; biologics available since…
Primary barrieraccess/practice
Full remission profile →

Remission & chronicity

Spontaneous remission
60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent; moderate-severe adult AD: <15% spontaneous clearance at 5 years
Best-intervention remission
Dupilumab (anti-IL-4Rα): 51% IGA 0/1 (clear/almost clear) at 16 weeks in SOLO trials; tralokinumab (anti-IL-13): 38% clear/almost clear; baricitinib (JAK1/2i): 16% EASI-100 (complete clearance) at 16 weeks; upadacitinib (JAK1i): 28-40% EASI-100; near-complete clearance now achievable for most patients
Gap size
Large — most patients managed with topical steroids for decades without biologic assessment; biologics available since 2017 but reach only a fraction of eligible patients
Primary barrier
access/practice
Dupilumab approved 2017 but still not first-line in most health systems due to cost ($36,000/year); step therapy requirements force patients through years of topical steroids and immunosuppressants first; racial disparities in specialist access and biologic prescribing
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “Atopic Dermatitis (Eczema)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 0-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.